Proactive - Interviews for investors

Avalon GloboCare Corp (NASDAQ:ALBT) director Michael Mathews talked with Proactive's Stephen Gunnion about the development of RPM's innovative AI video production platform, Catch-Up. Mathews, who also serves as CEO of RPM, described the platform as the first of its kind - capable of producing videos automatically using generative AI and large language models. The system is designed to support content creators, particularly podcasters, by automating video production. According to Mathews, “This is a system that will scrape a YouTube video... and then through intelligent large language model prompting, you create opening and closing commentary.” This is delivered using a personal avatar and published across social media platforms based on a schedule. Mathews outlined a two-phase marketing plan. The first involves targeting podcasters and creators via email by content verticals such as politics, pop culture, and finance. The second phase will be a YouTube video campaign planned for mid-2026. He also emphasized the scalability of the platform, highlighting a goal of securing several hundred licenses in the first six months and thousands by the end of the first year. A provisional patent has already been filed with the USPTO. Looking ahead, RPM is planning a personalization phase to expand scraping capabilities across multiple platforms and is open to acquiring synergistic AI products. For more updates, visit Proactive's YouTube channel. Don't forget to like this video, subscribe to the channel, and enable notifications for future content. #AvalonGloboCare #RPM #AIvideo #GenerativeAI #SaaSplatform #ContentCreation #Podcasters #AItechnology #StartupStrategy #MichaelMathews #ArtificialIntelligence #VideoAutomation #TechInterview

Tonix Pharmaceuticals Holdings CEO Dr. Seth Lederman joined Steve Darling from Proactive to announce that the company has secured exclusive worldwide licensing rights to TNX-4900, a highly selective small-molecule Sigma-1 receptor (S1R) antagonist with demonstrated analgesic activity across multiple preclinical models of neuropathic pain. Lederman explained that Sigma-1 receptor antagonism has attracted growing scientific and clinical interest as a promising new class of non-opioid, non-addictive pain therapies. Tonix has leveraged computer-aided and artificial intelligence–driven drug design approaches to develop this next generation of selective S1R antagonists. TNX-4900 has demonstrated robust and durable pain-relief activity in several validated neuropathic pain models, alongside an encouraging preclinical safety profile. TNX-4900 emerged from a structure-based drug design program led by researchers at Rutgers University, which generated a series of potent and selective triazole-based Sigma-1 receptor antagonists. The compound binds to the human Sigma-1 receptor with nanomolar affinity (Ki = 7.5 nM), exhibits greater than 100-fold selectivity over the Sigma-2 receptor, and shows strong penetration of the blood–brain barrier. In addition, TNX-4900 demonstrates favorable pharmacokinetic characteristics, including attractive absorption, distribution, metabolism, and elimination (ADME) properties and an oral bioavailability of approximately 28%. These attributes support its potential suitability for chronic oral administration in pain indications. In preclinical models of both diabetic neuropathy and chemotherapy-induced neuropathic pain, TNX-4900 produced significant and sustained reductions in pain-related behaviours following both acute and repeated dosing. Importantly, these analgesic effects were observed without evidence of tolerance development or motor impairment, key limitations associated with many existing pain therapies. Tonix plans to advance TNX-4900 through expanded pharmacokinetic, formulation, and safety studies as part of an IND-enabling development program. According to Lederman, the company believes TNX-4900 represents a compelling opportunity to address a large unmet medical need with a differentiated, non-opioid therapeutic option for patients suffering from neuropathic pain. #proactiveinvestors #tonixpharmaceuticalsholdingcorp #nasdaq #tnxp #Biotech #kidneydisease #massachusettsgeneralhospital #massgeneral #VaccineDevelopment #ClinicalTrials #PharmaceuticalNews #MedicalResearch #WHO #GlobalHealth #InfectiousDiseases #SethLederman #ChronicPain #TNX4900 #TONMYA #FibromyalgiaTreatment #NeuropathicPain #PostherpeticNeuralgia #FDAApproval #PharmaNews #ProactiveInvestors

Arrow Exploration CEO Marshall Abbott joined Steve Darling from Proactive to provide an operational update on activity at the Mateguafa Attic field, located on the Tapir Block in Colombia's prolific Llanos Basin, where Arrow holds a 50% beneficial interest. The update highlighted the successful drilling, completion, and initial production performance of the Mateguafa HZ7 (M-HZ7) horizontal well. Abbott confirmed that the M-HZ7 well was spud on November 22, 2025, and reached its target depth on December 4, 2025. The well was drilled safely, on time, and on budget to a total measured depth of 14,253 feet, corresponding to a true vertical depth of 8,440 feet. During drilling, the well intersected multiple hydrocarbon-bearing intervals, reinforcing the prospectivity of the Mateguafa field. The company has now brought the M-HZ7 well onto production from the Carbonera C9 formation. The well includes approximately 4,053 feet of horizontal oil pay within a clean sandstone reservoir exhibiting strong reservoir characteristics, including an average porosity of 23% and high resistivity readings. Following perforation, an electric submersible pump (ESP) was installed to support production operations. In addition to the C9 interval, the well also encountered approximately 20 feet of net oil pay, on a true vertical depth basis, within the Carbonera C7 formation, providing further upside potential from stacked reservoirs in the field. The M-HZ7 well was initially placed on production at a heavily restricted setting, using a 25/128 choke and a pump frequency of 30 Hz. At these conservative conditions, the well is producing approximately 1,694 barrels of oil per day on a gross basis, or 847 barrels of oil per day net to Arrow. The produced oil has an API gravity of 30.6°, with a low water cut of approximately 4%, primarily attributed to completion fluids and minor formation water. Abbott noted that the well continues to clean up and that performance will be closely monitored as operating parameters are gradually optimized. Abbott also provided updates on the broader Mateguafa development program, including activity at the Mateguafa-6, Mateguafa-5, and Mateguafa-8 wells. Following the tie-in and production start-up of the M-8 well, Arrow plans to drill the Mateguafa-9 (M-9) well. This well is designed primarily as a delineation and water disposal well to support ongoing development across the Mateguafa area. The M-9 well will be the final well drilled under Arrow's 2025 drilling program. It is planned as a large step-out well located outside the currently interpreted limits of the reservoir. While its primary purpose is water disposal, Abbott noted that the well could potentially become a producer if the reservoir extends beyond current seismic interpretations. After completing the M-9 well, Arrow intends to continue drilling additional horizontal and vertical development wells within the Mateguafa field before moving the rig to the Icaco prospect, where the company plans to drill its first exploration well at that location. #proactiveinvestors #arrowexplorationinc #aim #axl #tsxv #axl #ColombiaEnergy #MarshallAbbott #Q1Results #OilDrilling #EnergyInvestment #SeismicSurvey #WaterDisposal #PrepaymentDeal #ExplorationAndProduction #LlanosBasin #EnergySector #ProactiveInvestors

U.S. Gold Corp. Chairman Luke Norman joined Steve Darling from Proactive to provide an update on the company's financing activities following the successful closing of a private placement that raised approximately $31.2 million in gross proceeds. The financing represents a significant step forward as the company advances toward development of its flagship CK Gold Project in Wyoming. Norman explained that the offering was priced based on the closing price of U.S. Gold's common shares on Monday, December 15, 2025, which was $16.91 per share. The pricing reflects an approximate 4% discount to the market close, a structure designed to balance investor participation while minimizing dilution. The warrants issued in connection with the private placement are immediately exercisable and have a two-year term from the date of issuance, providing additional potential upside for participants. The company intends to deploy the net proceeds strategically across several priorities. A primary focus will be funding initial development costs at the CK Gold Project, which has now entered the final stage of its Definitive Feasibility Study (DFS). In addition, funds may be allocated toward potential land acquisitions, further exploration across the company's property portfolio, and general working capital to support ongoing operations. Norman emphasized that U.S. Gold is moving “full steam ahead” with the CK Gold Project, highlighting that site preparation activities are already underway. As the DFS progresses toward completion, the company believes it is well positioned to transition from advanced study work into the early stages of project development. With a strengthened balance sheet and capital in place, U.S. Gold Corp. expects 2026 to be a pivotal year as it works to de-risk the CK Gold Project, advance permitting and development planning, and create long-term value for shareholders. #proactiveinvestors #usgoldcorp #nasdaq #usau #mining #gold #copper USGoldCorp, #Mining #CKGoldProject #MiningInvestment #GoldMining #FeasibilityStudy #PowerInfrastructure #ProjectFinancing #MiningDevelopment #GoldStocks #WyomingMining

Graphene Manufacturing Group CEO Craig Nicol joined Steve Darling from Proactive to provide an update on the company's commercialisation progress, highlighting a major regulatory milestone for its THERMAL-XR® ENHANCE graphene coating product. GMG announced it has received and accepted the United States Environmental Protection Agency's consent notice approval conditions under the Pre-Manufacture Notice (PMN) process, clearing an important step toward full market entry in the United States. The EPA consent notice represents a significant achievement for GMG, as the PMN program is designed to ensure the safety and environmental suitability of new chemical substances introduced into the U.S. market. With this approval milestone in place, THERMAL-XR® ENHANCE is positioned to offer meaningful energy savings and enhanced corrosion resistance for U.S. consumers and commercial users across a range of industrial and building applications. Nicol explained that, upon receipt of the fully signed consent notice from the EPA—expected early in the new year—the first commercial shipment of THERMAL-XR® ENHANCE will be sent to Nu-Calgon. The product will be distributed and resold under the name “Nu-Calgon CoolWorx® powered by GMG Graphene,” marking GMG's initial commercial rollout of the technology in the U.S. market. Beyond coatings, Nicol also provided an update on GMG's Graphene Aluminium-Ion (G+AI) Battery technology, which is being developed in collaboration with the University of Queensland under a Joint Development Agreement with Rio Tinto, one of the world's largest mining and metals companies. The project is also supported by the Battery Innovation Center of Indiana in the United States, strengthening the development and validation framework for the technology. GMG reported that, at its current stage of development, the G+AI Battery demonstrates performance characteristics comparable to high-power Lithium Titanate Oxide (LTO) batteries, which typically sell at premium prices of up to US$1,500 per kilowatt-hour. Importantly, GMG believes its graphene-based battery can be manufactured at a substantially lower cost, enabling pricing below that of LTO batteries. In 2025, global sales of LTO batteries reached approximately US$5.6 billion, underscoring the scale of the addressable market. Looking ahead, GMG management believes continued optimization of the cathode, anode, electrolyte, and overall component weight could enable the G+AI Battery to achieve energy densities of more than 150 Wh/kg when charged in one hour, and over 75 Wh/kg with ultra-fast six-minute charging. The company sees these performance targets as key drivers for future commercial competitiveness across a wide range of global energy storage applications. #GrapheneManufacturingGroup #CraigNicol #THERMALXR #GLubricant #REACHapproval #HVACR #CleanTech #GrapheneTechnology #EnergyEfficiency #SustainableTech #NuCalgon #SprayAcademy #EPAapproval #EuropeanMarket #ProactiveInvestors

Medicus Pharma Chief Medical Officer Dr. Faisel Mehmud joined Steve Darling from Proactive to announce that the company has entered into a non-binding letter of intent with Reliant AI, a decision-intelligence company specializing in generative artificial intelligence for the life sciences. The proposed collaboration is focused on developing an AI-powered data analytics platform designed to enhance clinical trial execution through advanced, data-driven insights. Reliant AI is a privately held company founded by former DeepMind and Google Brain researchers Karl Moritz Hermann and Marc Bellemare, alongside life sciences expert Richard Schlegel. The company combines state-of-the-art machine learning techniques with deep biomedical expertise to automate data-intensive workflows across the life sciences, ranging from systematic literature reviews to commercial success prediction. Its platform is designed to enable biopharma teams to make faster, more informed, evidence-based decisions throughout the research and development lifecycle. Dr. Mehmud explained that the proposed platform would integrate Reliant AI's proprietary generative AI technology with Medicus' clinical, operational, and internal datasets. The goal is to strengthen data-driven decision-making across Medicus' clinical pipeline, with a particular focus on improving trial efficiency. Key anticipated capabilities include dynamic clinical-site selection, enhanced patient stratification, and more accurate enrollment forecasting. The initial phase of the collaboration is expected to focus on dynamic site selection supported by targeted patient-stratification analyses for an upcoming Teverelix clinical study, which is planned to begin in 2026. Subject to the execution of definitive agreements, Medicus expects the data analytics platform to be deployed initially in support of a Medicus-sponsored study during the Q2 to Q4 2026 period. There is also potential for the platform to be expanded to support a larger, late-stage clinical study planned for 2028, potentially in collaboration with a development or commercial partner. Medicus Pharma is currently advancing its SKNJCT-003 Phase 2 clinical study, which is being conducted across nine clinical sites in the United States. The study, which began randomizing patients in August 2024, is a randomized, double-blind, placebo-controlled, triple-arm proof-of-concept trial evaluating a non-invasive treatment for basal cell carcinoma of the skin. The study uses Medicus' novel, patent-protected, dissolvable doxorubicin-containing microneedle array (D-MNA) technology, highlighting the company's broader commitment to innovation in both therapeutic development and clinical execution. #proactiveinvestors #nasdaq #mdcx #tsxv #mdcx #pharma #Biotech #CancerTreatment #ClinicalTrials #FDAApproval #SkinCancer #HealthcareInnovation #Investing #MedicalResearch #SkinCancer #BasalCellCarcinoma #BiotechNews #CancerResearch #GorlinSyndrome #BasalCellCarcinoma #CompassionateUse #FDAApproval #RareDiseaseTreatment #NoninvasiveTherapy #BiotechNews

Nextech3D.ai CEO Evan Gappelberg joined Steve Darling from Proactive to announce that the company has successfully completed its due diligence process and is preparing to close its acquisition of Krafty Labs on January 2, 2026, subject to customary closing conditions, including approval from the Canadian Securities Exchange (CSE). Gappelberg explained that Krafty Labs brings a highly attractive blue-chip customer roster that includes global technology and enterprise leaders such as Google, Microsoft, Netflix, Oracle, Yelp, ZoomInfo, Spotify, and Meta, among others. In addition to its strong customer base, Krafty Labs has generated approximately $1.2 million in year-to-date 2025 revenue, supported by robust gross margins of roughly 72%, underscoring the scalability and profitability of its platform. Management believes the acquisition will significantly enhance Nextech3D.ai's AI-first event and engagement ecosystem by adding enterprise-grade capabilities that complement its existing technology stack. The integration of Krafty Labs' advanced engagement tools with Nextech3D.ai's in-person, virtual, and hybrid event solutions is expected to expand the company's reach into higher-value enterprise and association customers. Gappelberg noted that the combined platform is positioned to drive higher average contract values, foster deeper and longer-term customer relationships, and unlock new monetization opportunities across a broad range of event formats. By strengthening its foothold in the enterprise market, Nextech3D.ai aims to accelerate revenue growth while reinforcing its position as a leading provider of AI-powered event and experience technologies. #nextech3d.al #otcqx #nexcf #cse #ntar #EvanGappelberg #ARway #AugmentedReality #SpatialMapping #IndoorNavigation #MapDynamics #EventTech #TradeShowSolutions #TechStocks #ARRevenueGrowth #3DTechnology #ProactiveInvestors #aws #amazonwebservice #tickets #kraftylab

HeLIX Exploration PLC (AIM:HEX, OTCQB:HHEXF) CEO Bo Sears talked with Proactive's Stephen Gunnion about the company's imminent transition into helium production at its Rudyard project in Montana. Sears confirmed that the PSA compressor, described as the "long lead item," is now en route to site, marking the final step in completing the processing unit. “Once that is delivered and installed, we will be a helium producing company,” Sears told Proactive, emphasizing that all other infrastructure is already in place. The company expects only minor fine-tuning once all components are connected. He noted that despite the upcoming holiday season slowing some activity, HeLIX remains on track. Sears also discussed expanded acreage at Rudyard, which he said has revealed greater potential with each well drilled. HeLIX is waiting for a suitable weather window post-Christmas to continue drilling operations, which were recently delayed by severe weather conditions. On the commercial side, Sears said discussions remain active around helium offtake agreements and potential hydrogen-related partnerships. However, final commitments will only follow first production. “It's just going to take a few days to get this thing plumbed together and in operation mode,” Sears added. “We are really excited about our future here.” Visit Proactive's YouTube channel for more company interviews and updates. Don't forget to like this video, subscribe to the channel, and turn on notifications so you don't miss future content. #HeliumProduction #HeLIXExploration #MontanaEnergy #BoSears #RudyardProject #PSACompressor #EnergyStocks #HydrogenPartnerships #NaturalResources #ProactiveInvestors

Oakmount & Partners Ltd managing director Glenn King talked with Proactive's Stephen Gunnion about the progress investee company Intergroup Mining has made toward its planned listing on the Nasdaq stock exchange. King explained that the submission of legal and accounting documentation to the US Securities and Exchange Commission (SEC) marks a “significant milestone” for Intergroup Mining. “It now means that the company, from a tangible perspective, is just one stage closer to its debut listing,” he said. He noted that while the SEC now enters a review phase, Intergroup can respond to any questions and continue progressing toward its IPO. King also outlined the key compliance steps remaining and highlighted the importance of demonstrating strong financials, clear business plans, and limited share dilution. From an investor perspective, King said a US listing would deliver strategic benefits. “You're on a notable tier one exchange with deep pools of liquidity,” he noted, adding that it may also position Intergroup as an acquisition target in the coming years. He added that Intergroup Mining produces kaolin, metakaolin, and is also positioned to begin gold production, noting that the project is considered a "legacy mine" with a life expectancy of more than 100 years. Updates are expected around late January or early February, depending on SEC feedback. For more interviews like this, visit Proactive's YouTube channel. Don't forget to like the video, subscribe, and turn on notifications for future content. #IntergroupMining #NasdaqIPO #OakmountPartners #MiningStocks #Kaolin #GoldMining #Metakaolin #USListing #SECfiling #InvestorUpdates #IPOProcess #CapitalMarkets #ProactiveInvestors

Dekiln CEO Dr Aled Roberts talked with Proactive's Stephen Gunnion about the company's breakthrough in sustainable ceramic tile production and how £3 million in funding from the Royal Academy of Engineering's Green Future Fellowship program will help scale the technology. Roberts explained that conventional ceramic tiles have a high carbon footprint due to the energy-intensive kiln-firing process. Dekiln has developed an alternative by mimicking natural processes seen in seashells and tooth enamel, creating tiles that function and feel like ceramics without requiring high-temperature firing. “Our materials are made with very high recycled content,” said Roberts. The tiles are manufactured using recycled gypsum, plastics, and calcium sulfate, combined with a bio-based active ingredient. This not only lowers energy input but significantly reduces carbon emissions in the manufacturing process. The funding will support Dekiln's transition from lab-scale production—currently at one square metre of tiles per day—to commercial-scale manufacturing. The company has recently moved into a new facility and upgraded to an entry-level commercial press, representing the first step in its scale-up journey. It now aims to work with a UK-based industrial partner to build a pilot plant. For more insights into Dekiln's progress and the Frontier IP Group, PLC (LSE:FIPP) innovative portfolio, visit Proactive's YouTube channel, and don't forget to like this video, subscribe, and enable notifications for updates on future interviews and company developments. #Dekiln #SustainableMaterials #GreenTechnology #NetZero #RoyalAcademyOfEngineering #ClimateTech #RecycledMaterials #CeramicInnovation #LowCarbon #Cleantech

M2i Global CEO Alberto Rosende joined Steve Darling from Proactive to provide an update on the company's strategic initiatives, including progress on its merger with Volato and a new offtake agreement with Next-Gen. Rosende confirmed that the long-anticipated merger with Volato is moving forward after delays caused by a recent government shutdown. “We were able to push it out quickly,” he said, referencing the company's SEC filing response. The shareholder meeting to approve the merger is scheduled for February 26th, 2026, with the company aiming to close the deal by the end of the first quarter. This milestone is expected to strengthen M2i Global's software development capabilities, particularly in applications supporting critical mineral supply chains. The CEO also shared details about a new partnership with Next-Gen, which operates a proprietary cathode material process. The facility in Australia will be the first of its kind outside China, and M2i Global has secured an exclusive offtake agreement for the material, expected to begin delivery in approximately two years. Rosende described the development as “really exciting news that we'll be able to bring that to the United States,” underscoring the strategic importance of securing a stable, non-China-based supply of cathode materials for the North American market. Looking ahead to 2026, Rosende emphasized Volato's critical role in the company's broader Critical Minerals Reserve project. Volato will provide software solutions for material tracking, inventory management, and integration with partner operations. A pilot program is planned to validate the technology, ensuring seamless coordination across the supply chain and providing real-time analytics for strategic decision-making. Rosende concluded that these developments position M2i Global to enhance its operational capabilities, secure critical supply sources, and expand its footprint in the rapidly growing market for advanced battery materials and critical minerals. #proactiveinvestors #m2iglobalinc #otcqb #mtwo #CriticalMinerals #SupplyChainSecurity #StrategicMinerals #USDefense #EconomicSecurity #BlockchainLogistics #CriticalMinerals #NevadaMining #parslee #volato #gallium

Replenish Nutrients CEO Neil Wiens joined Steve Darling to outline the company's transition from development into full commercialization, highlighted by strategic licensing agreements and a significant partnership in the United States. Wiens described 2025 as a pivotal transformation year for Replenish Nutrients. During this period, the company successfully completed its proof-of-concept phase, finalized key intellectual property filings, and moved into commercial-scale operations. “We are physically into that next phase where the licensing deals are real,” Wiens said, emphasizing that the business is now executing on its commercialization strategy rather than preparing for it. A central focus of the discussion was Replenish Nutrients' recently announced U.S. licensing agreement with Farmers Union Enterprises. The agreement provides the company with access to approximately 70 million acres of farmland, representing a substantial commercial opportunity. Wiens highlighted the favorable timing of the deal, noting its alignment with a newly announced US$700 million USDA regenerative agriculture program. He described the timing as “absolutely fantastic,” as policy support and grower interest in soil health solutions continue to accelerate. Operationally, Wiens confirmed that the company's Minnesota-based production facility is on track to become operational by June. In parallel, Replenish Nutrients is actively engaged in discussions to expand its footprint into four additional U.S. states. Beyond North America, the company is also evaluating opportunities in Brazil, citing strong synergies in nutrient usage and alignment with its existing supply chain partner. Wiens reiterated that farmer return on investment remains the cornerstone of adoption. “If I can get soil health plus keep my yield the same or better and also start decreasing my fungicide and pesticide use – I win as a farmer,” he said, underscoring the value proposition Replenish aims to deliver to growers. Looking ahead to 2026, Replenish Nutrients plans to scale its global presence while maintaining its operational and corporate base in Canada, positioning the company to benefit from the growing global focus on regenerative agriculture and sustainable food production. #proactiveinvestors #replenishnutrientsholdingscorp #cse #erth #otc #vvivf #RegenerativeAgriculture #FertilizerInnovation #SustainableFarming #CropGrowth #NeilWiens #AgricultureNews #Farming2025 #ProactiveInvestors #SustainableSolutions #Agritech #FertilizerInnovation #MJAgSolutions #PelletFertilizer #ProbioticSoil #BeisekerFacility #CanadianAgriculture

ProPhase Labs CEO Ted Karkus joined Steve Darling from Proactive to announce that the company has entered into a non-binding Letter of Intent (LOI) regarding a proposed reverse merger transaction with Advanced Biological Laboratories (ABL), a European biotechnology and MedTech group. Under the proposed structure, Advanced Biological would become the majority owner of the combined public entity, while ProPhase's existing operations would continue as sister companies to a newly formed U.S. subsidiary expected to remain under ProPhase's current management team. Karkus emphasized that the transaction remains subject to the execution of definitive agreements, regulatory approvals, and board authorization. However, the parties have discussed a preliminary, non-binding valuation framework that could imply an enterprise value of up to approximately US$30 million for ProPhase's legacy business. This framework is intended to provide a basis for ongoing negotiations rather than a final valuation. As outlined in the LOI, and subject to applicable law and final documentation, ProPhase Labs may declare a special cash dividend of up to US$10 million payable to shareholders of record on a date to be determined. Importantly, any such dividend would be distributed separately and would not be part of the merged operating company. In addition, all Crown Medical Collections receivables are expected to be carved out and retained exclusively for the benefit of current ProPhase shareholders, further preserving value for existing investors. Advanced Biological Laboratories would contribute its global biotechnology and MedTech infrastructure to the combined company, including advanced health data processing platforms, cloud-based computing capabilities, and access to international financing resources. The combination is intended to create a more diversified healthcare technology platform with expanded global reach, while allowing ProPhase to unlock value for shareholders through potential cash distributions and retained assets. #proactiveinvestors #prophaselabs #nasdaq #prph #biotech #genomics #genomesequencing #ProPhaseLabs #AdvancedBiologicalLaboratories #ReverseMerger #LOI #Biotechnology #MedTech #HealthcareTechnology #StrategicTransaction #ShareholderValue #SpecialDividend #NasdaqListed #GlobalHealthcare #HealthData #CloudComputing #LifeSciences #MergersAndAcquisitions

Cabbacis CEO Joe Pandolfino joined Steve Darling from to discuss the company's strategic preparations to enter the U.S. market with its proprietary low-nicotine tobacco products. Cabbacis is a federally licensed tobacco product manufacturer with a robust intellectual property portfolio that includes 35 issued patents worldwide, covering its iBlend™ cigarettes and vaporizer pod technology. The company operates out of a manufacturing facility in Niagara Falls, New York, and is led by a management team that brings more than 50 years of combined experience in the tobacco industry. Pandolfino explained that iBlend™ products have been specifically engineered to align with anticipated regulatory changes in the United States. He noted that the U.S. Food and Drug Administration is advancing a rule that could require a reduction of nicotine levels in all cigarettes sold in the country by approximately 95%. “The FDA is moving forward a rule which would mandate the reduction of nicotine in all cigarettes sold in the United States by about 95%,” Pandolfino said, positioning iBlend™ as a potential solution for a post-regulation tobacco market. Cabbacis' strategy centers on improving consumer acceptance of very low nicotine cigarettes, which multiple peer-reviewed studies have shown can significantly reduce smoking frequency and nicotine dependence. Pandolfino highlighted that the company's proprietary blend incorporates hemp alongside tobacco, a formulation that internal focus group research indicates is more appealing to smokers than traditional very low nicotine products. Looking ahead, Cabbacis plans to conduct additional studies in the first quarter of 2026 to support regulatory submissions. The company is targeting the submission of a Pre-Market Tobacco Application (PMTA) to the FDA for its iBlend™ products in the first half of 2026. Pandolfino told Proactive that achieving FDA authorization would mark a major milestone and could position Cabbacis as an early mover in a rapidly evolving, regulation-driven U.S. tobacco landscape. #proactiveinvestors #cabaccis #otcqb #cabi #Cabbacis #iBlend #LowNicotine #TobaccoInnovation #FDARegulation #PMTA #NicotineReduction #HarmReduction #TobaccoIndustry #SmokingCessation #RegulatoryStrategy #IntellectualProperty #PatentedTechnology #USMarketEntry #ConsumerHealth

Happy Creek Minerals CEO Steve Gray joined Steve Darling from Proactive to share details of the company's latest assay results from its 2025 diamond drilling program at the Fox Tungsten Project in British Columbia. The recently completed program focused on expanding the known tungsten mineralization at the Ridley Creek (RC) and BN zones, two of the project's most prospective target areas. During September and October, Happy Creek completed a total of 18 diamond core drill holes at the Fox Project, drilling an aggregate 2,176 metres. The primary objective of the program was to test extensions of known calc-silicate horizons that host tungsten mineralization and to better define the geometry and continuity of these zones beneath areas of limited surface exposure. Gray told Proactive that drilling at the Ridley Creek zone successfully confirmed strong continuity of the calc-silicate horizon and expanded the mineralized system to the southwest. Importantly, the mineralization remains clearly open to the west beneath Deception Mountain, highlighting significant potential for further resource growth. One of the standout results from the RC zone came from hole F25-13, which intersected 1.18 metres grading an impressive 6.83% WO₃ at a downhole depth of 31.2 metres. At the BN zone, drilling on the northwest side intersected multiple calc-silicate horizons, supporting a stacked-layer geological model. One of these mineralized horizons was intersected at a depth of approximately 200 metres below surface, indicating the system extends well beyond previously tested depths. Results from hole F25-16 included 1.00 metre grading 0.88% WO₃ from 105.0 metres downhole, as well as a deeper intercept of 1.65 metres grading 0.57% WO₃ from 218.3 metres downhole. According to Gray, the 2025 drilling program clearly demonstrates that the calc-silicate horizons and associated tungsten mineralization at both the RC and BN zones remain open to the west and north beneath Deception Mountain. The results also point to the potential for additional, yet-to-be-discovered horizons at depth, reinforcing the Fox Project's upside as a growing tungsten system. Happy Creek plans to incorporate the new assay and geological data into its ongoing interpretation work as it evaluates next steps for further drilling and resource expansion at the Fox Tungsten Project. #proactiveinvestors #happycreekmineralsltd #tsxv #hpy #Tungsten #WO3 #CriticalMinerals #BritishColumbiaMining #DrillResults #DiamondDrilling #MineralExploration #ResourceExpansion #CalcSilicate #TungstenMining #StrategicMetals #ExplorationSuccess #MiningNews #ProactiveInvestors

Ilika CEO Graeme Purdy joined Steve Darling from Proactive to announce that the company has begun shipping prototype Stereax M300 solid-state batteries to customers, marking a significant commercial milestone for the business. The initial shipments represent the first delivery of the M300 product and will be allocated to the 21 customers that currently make up Ilika's existing order book. Many of these customers have already evaluated earlier-generation Stereax batteries supplied from Ilika's UK pilot production line, and the new prototype deliveries are intended to support further validation and system-level integration. In parallel, a portion of the initial M300 batches will be retained by Ilika for its extensive internal testing programme. This programme is designed to generate a broader and more robust body of performance data aligned with demanding use cases, particularly within active implantable medical devices. Purdy told Proactive that the potential applications for the Stereax M300 span a wide range of implantable and wearable medical technologies. These include powering implanted sensors, neurostimulators, orthopaedic implants, orthodontic wearables, and ophthalmology devices. He explained that Stereax's small footprint, combined with enhanced charging capability, makes it especially well suited for AIMDs. Key benefits of the Stereax technology include reduced surgical time, greater flexibility in placing implants closer to the point of therapy, long operational life, and the convenience of user recharging at home. In addition, the battery's ability to support Bluetooth radio functionality opens the door to advanced connected medical applications. As part of the commercialization process, Ilika and its strategic manufacturing partner, Cirtec Medical Corp, will actively gather feedback from this initial customer group. The insights gained will be used to verify customer experience and performance expectations before scaling up production. This latest milestone advances the 10-year manufacturing agreement signed in August 2023, under which Cirtec Medical, a leading US-based medical device manufacturer, will produce Ilika's full Stereax battery portfolio. The commencement of prototype shipments represents a key step toward broader commercial deployment of Ilika's solid-state battery technology in medical markets. #proactiveinvestors #ilika #aim #ika #goliathautomatedline #SolidStateBatteries #Stereax #GoliathBattery #BatteryTech #GraemePurdy #EVBatteries #EnergyStorage #CirtecMedical #JaguarLandRover #UniversityOfOxford #ProactiveInvestors

Regan Capital CIO Skyler Weinand joined Steve Darling from Proactive to share news about the dynamics of the fixed income markets, interest rates, and mortgage-backed securities. Weinand outlined Regan Capital's focus on U.S. mortgage-backed securities, noting the company manages around $3.6 billion across mutual funds, ETFs, and a UCITS ETF for non-U.S. investors. “Mortgages are about $13.5 trillion outstanding,” Weinand said, emphasizing the scale of the U.S. mortgage market and the challenges retail investors face accessing it directly. He discussed how recent Federal Reserve rate cuts have not lowered long-term interest rates. In fact, the yield on longer-term bonds and mortgage rates have increased. Weinand stated, “Mortgage rates are actually higher today than they were last September.” He cautioned that loose financial conditions, robust corporate balance sheets, and rising equity markets suggest rates could move higher, even if the Fed implements more cuts. He noted growing corporate debt issuance, with examples like Google's 50-year bond at a 5.7% coupon. For investors, Weinand recommended focusing on short-duration and floating-rate securities, especially those backed by U.S. government guarantees, which can offer higher yields with lower volatility. #FixedIncome #InterestRates #MortgageBonds #SkylerWeinand #ReganCapital #BondMarket #ETFs #ShortDurationBonds #FederalReserve #FinancialMarkets #InvestmentStrategy #FloatingRate #ProactiveInvestors

Standard Uranium CEO Jon Bey joined Steve Darling from Proactive to discuss the company's operational progress throughout 2025 and outline its strategic roadmap heading into 2026, highlighting a year marked by successful capital raising, advancing exploration programs, and the expansion of its joint venture portfolio. Bey noted that Standard Uranium raised nearly C$7.0 million during 2025, providing the financial foundation to advance multiple exploration initiatives across its project portfolio. A significant portion of that capital has been allocated to the Davidson River project, which is now fully funded and preparing for the largest drill program in the project's history. Drilling at Davidson River is scheduled to begin in late May 2026 and is expected to be a major catalyst for the company. One of the year's key developments was the return of 100% ownership of the Sun Dog project to Standard Uranium after joint venture partner Arrow Energy was unable to meet its funding commitments. Bey explained that this outcome has positioned the company to re-engage the market, confirming that multiple confidentiality agreements have already been signed with interested joint venture partners. Subject to final agreements, drilling at Sun Dog is expected to resume in late summer 2026. The company also continued to advance its project generator business model by securing new joint venture agreements. Standard Uranium entered into a partnership with Aventis on the Corvo project and a separate agreement with Collective Metals on the Rocas project. Both projects are on track to begin drilling in the first quarter of 2026, further diversifying the company's near-term exploration pipeline. Looking ahead, Bey confirmed that Standard Uranium's full management and technical team will attend the Vancouver Resource Investment Conference in January 2026. The company plans to meet with investors and stakeholders at the event to provide updates on its exploration plans and outline anticipated catalysts for the year ahead. #proactiveinvestors #standarduraniumltd #tsxv #stnd #otcqb #sttdf #mining #uranium #corvoproject #UraniumExploration #AthabascaBasin #DavidsonRiver #MiningInnovation #Geophysics #AmbientNoiseTomography #ResourceInvesting #FleetSpace #UraniumDiscovery #MiningNews

1911 Gold Corporation Chairman Gary O'Connor joined Steve Darling from Proactive to announce the start of a 2,200-metre diamond drilling program at the Ogama-Rockland gold deposit, located southeast of the company's True North Gold Project. The program has already commenced, with one surface diamond drill rig mobilized to site. The drilling campaign is designed to support both resource expansion and confirmation, as the company continues to advance its understanding of the Ogama-Rockland deposit and its potential integration with existing infrastructure at True North. The Ogama-Rockland gold deposit currently hosts an NI 43-101 compliant inferred mineral resource of approximately 1.28 million tonnes grading 8.17 grams per tonne gold, containing an estimated 337,000 ounces of gold. O'Connor emphasized that the deposit's high-grade nature and shallow mineralization make it an attractive near-term development opportunity. According to O'Connor, the planned eight drill holes will focus on confirming the updated geological model and testing extensions of high-grade, quartz-vein-hosted gold mineralization at relatively shallow depths. Drilling will target both down-dip and along-strike extensions of the main vein system, as well as newly identified parallel structures that emerged from recent relogging and resampling of historical drill core and updated geological modelling. In addition to expanding the resource base, the company plans to conduct metallurgical test work on drill core samples collected during the program. This testing will evaluate the suitability of processing material from Ogama-Rockland at the existing True North processing facility, potentially providing a streamlined development pathway and capital efficiencies. Following completion of the drill program and analysis of the results, 1911 Gold plans to deliver an updated underground mineral resource estimate in the first half of 2026. The company views this program as an important step in unlocking additional value at Ogama-Rockland while leveraging its established infrastructure at the broader True North project. #proactiveinvestors #1911goldcorporation #1911gold #tsxv #aumb #otcqx #aumbf #GoldExploration #MiningNews #TrueNorthGold #OgamaRockland #DrillingUpdate #PEA #ResourceUpdate #GoldMiningCanada #TSXV #JuniorMining

BioVie CEO Cuong Do joined Steve Darling from Proactive to provide an update on the company's recent progress across its two lead drug candidates, Bezisterim and BIV201, as BioVie positions itself for multiple clinical and regulatory catalysts in 2026. Bezisterim, an anti-inflammatory compound that blocks tumor necrosis factor alpha (TNF-α), is being evaluated across several indications, including Parkinson's disease, long COVID, and Alzheimer's disease. Do highlighted that the compound has delivered encouraging signals in prior studies, including improvements in muscle control and cognitive function, as well as evidence suggesting a slowing of biological aging. Building on these results, BioVie has launched a new clinical trial enrolling 60 patients with earlier-stage Parkinson's disease to evaluate Bezisterim as a standalone therapy. The goal of the study is to assess the drug's potential disease-modifying effects when administered earlier in the disease course. Topline data from this trial are expected in April or May of 2026. In parallel, BioVie is advancing a separate, larger clinical program targeting long COVID. The company is conducting a 200-patient trial designed to evaluate Bezisterim's ability to address persistent inflammatory mechanisms believed to drive many long COVID symptoms. Enrollment for this study is expected to be completed by February 2026. The trial is supported by a $13 million grant awarded to BioVie, underscoring the growing recognition of inflammation as a key contributor to long COVID. Do also provided an update on BioVie's second lead candidate, BIV201, which is being developed to treat ascites associated with late-stage liver disease. The company's Phase 2 trial of BIV201 was stopped early after interim data showed the drug reduced fluid accumulation by more than 50%, a clinically meaningful outcome in a difficult-to-treat patient population. Following discussions with the U.S. Food and Drug Administration, BioVie has now received feedback and authorization to advance BIV201 directly into a single Phase 3 clinical trial, streamlining the development pathway. Looking ahead, Do emphasized that BioVie expects 2026 to be a transformational year, with multiple clinical data readouts across programs and the potential initiation of a pivotal Phase 3 study. “2026 will be a big catalyst year for us,” he said, highlighting the breadth of opportunities across the company's pipeline. proactiveinvestors #biovieince #nasdaq #bivi #alzheimersdisease #dementia #Alzheimers #Dementia #NeurodegenerativeDiseases #BrainHealth #BioVie #CognitionImprovement #Neuroinflammation #SocialImpact #DementiaAwareness #ElderlyCare #Neuroscience #MemoryImprovement #AlzheimersResearch #HealthCrisis #DementiaSupport #BrainScience #GlobalHealth #AlzheimersSolution #Caregivers #HealthyAging #MentalHealth #MedicalResearch #DementiaPrevention #Neurology #WorldAlzheimersDay #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Tiziana Life Sciences CEO Ivor Elrifi joined Steve Darling from Proactive to announce a key clinical milestone, confirming that the first patient has been successfully dosed with intranasal foralumab in the company's Phase 2 randomized, placebo-controlled clinical trial in patients with early Alzheimer's disease (AD). This achievement follows the company's December 12, 2025 announcement that patient enrollment had begun, with first dosing expected imminently. The rapid progression from enrollment to dosing highlights strong site readiness and momentum for the study. The Phase 2 trial is designed to evaluate intranasal foralumab both as a standalone therapy and in combination with FDA-approved anti-amyloid treatments, including lecanemab (Leqembi®) and donanemab. By exploring combination therapy alongside monotherapy, Tiziana aims to assess whether targeting neuroinflammation can provide additive or complementary benefits to existing amyloid-reducing approaches. Elrifi explained that the trial is supported by compelling TSPO-PET imaging data, which demonstrate persistent and widespread microglial activation—a key marker of neuroinflammation—in patients with Alzheimer's disease. Notably, this neuroinflammatory activity has been shown to persist even after amyloid plaque reduction with therapies such as lecanemab. According to Elrifi, this evidence highlights a critical unmet need in Alzheimer's treatment: addressing residual neuroinflammation that may continue to drive disease progression. Intranasal foralumab is designed to modulate immune responses within the central nervous system and calm overactivated microglia, potentially reducing chronic inflammation associated with neurodegeneration. The intranasal delivery method is intended to provide targeted central nervous system exposure while minimizing systemic side effects. The Phase 2 study is a randomized, placebo-controlled trial assessing the safety, tolerability, and potential efficacy of intranasal foralumab in patients with early or mild Alzheimer's disease. Primary endpoints include changes in neuroinflammation as measured by TSPO-PET imaging, cognitive function outcomes, and biomarker changes related to amyloid and tau pathology. With the first patient now dosed, Tiziana Life Sciences advances into the next phase of clinical evaluation, positioning the company to generate meaningful data on whether addressing neuroinflammation—alone or in combination with anti-amyloid therapies—can improve outcomes for patients with early Alzheimer's disease. #proactiveinvestors #tizianalifescienceslts #nasdaq #tlsa #newceo #ivorelrifi #Foralumab #AlzheimersResearch #Neuroinflammation #BiotechNews #PETscan #ClinicalTrials #AlzheimersTreatment #PharmaUpdates #HealthcareInnovation

Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF) chief executive Manuel Llobet talked with Proactive's Stephen Gunnion about the granting of approval for Grassmuno, its grass allergy immunotherapy vaccine, in Germany - a significant milestone for the company. Llobet explained that the product is the first to be approved under the Therapieallergene-Verordnung (TAV) framework in the SCIT (subcutaneous immunotherapy) segment. The vaccine targets moderate to severe grass allergy sufferers, which he said represents the largest segment of the allergy market. "It's been a long journey, about one decade… tens of millions of investment to produce a state-of-the-art product," Llobet noted. He highlighted key advantages of the product: it is aluminium-free, adjuvanted, and designed as a short-course treatment — improving patient compliance and convenience. Allergy Therapeutics plans to replace its previous Pollinex Quattro Grass product in Germany with this new version, which has a higher concentration of active ingredients. Next steps include market expansion in Europe, Asia, and the US, leveraging clinical trials already coordinated with the FDA. The company is also exploring mutual recognition across EU territories via the Paul-Ehrlich-Institut. Llobet also touched on recent financials, pointing to portfolio restructuring and the shift from NPP products to registered treatments. Additionally, he discussed a potential dual primary listing in Hong Kong, aiming to engage Chinese investors and support expansion in the Asian market. Visit Proactive's YouTube channel for more company interviews. Don't forget to like this video, subscribe to the channel, and enable notifications to stay updated. #AllergyTherapeutics #GrassAllergy #Immunotherapy #SCIT #BiotechNews #VaccineApproval #HealthInnovation #EuropeanHealthcare #FDA #HongKongListing #ClinicalTrials #AllergyVaccine #PharmaUpdates #InvestingInBiotech #ProactiveInvestors

EnWave Corporation CEO Brent Charleton joined Steve Darling from Proactive to discuss the company's interim financial results for the fourth quarter and fiscal year ended September 30, 2025, highlighting a strong finish to the year driven by rising machine sales and expanding royalty streams. For the fourth quarter of fiscal 2025, EnWave reported revenue of C$6.2 million, a significant increase from C$3.6 million in the same quarter last year. The robust performance reflected the commissioning of one large-scale and six small-scale Radiant Energy Vacuum (REV™) machines, the sale of a refurbished 120-kilowatt unit, and continued fabrication work on two large-scale machines under existing contracts. Adjusted EBITDA for the quarter improved substantially to C$1.4 million, compared with C$0.45 million in Q4 2024. The improvement was attributed to higher machine sales volumes and a favorable production mix. Gross margin for the quarter also edged higher to 41%, up from 40% in the comparable period a year earlier. Royalty revenue showed mixed performance. Base royalties, excluding exclusivity payments, increased 31% to C$0.48 million, reflecting growing utilization of EnWave's technology by partners. However, total royalty revenue declined 25% to C$0.48 million due to a royalty partner in a Central American market choosing not to renew an exclusivity agreement. For the full fiscal year 2025, EnWave posted revenue of C$13.8 million, up sharply from C$8.2 million in fiscal 2024. Adjusted EBITDA turned positive at C$0.3 million, compared with a loss of C$1.5 million in the prior year, driven primarily by increased machine sales. Annual gross margin improved to 34% from 33% in 2024. Base royalties for the year rose 14% to C$1.8 million, while total royalty revenue decreased slightly to C$1.95 million. Selling, general and administrative expenses, including research and development, increased to C$5.6 million as the company invested more heavily in marketing, sales, and growth initiatives. During the fourth quarter and subsequent months, EnWave signed multiple new equipment purchase and license agreements with partners including Milne MicroDried, Dairy Concepts, BranchOut Food, Solve Solutions, and Shinyway International, further expanding its commercial footprint. #proactiveinvestors #enwavecorporation #tsxv #enw #DehydrationTech #VacuumMicrowave #RoyaltyBusinessModel #BluechipClients #FoodTech #BusinessNews #Investing #RadiantEnergyVacuum #Agritech #Procescir #DehydrationTechnology #FoodInnovation #SupplyAgreement #InvestmentNews #ProactiveInvestors #microdried

Nextech3D.ai CEO Evan Gappelberg and the company's newly appointed Global Head of Sales, James McGuinness, joined Steve Darling from Proactive to discuss the strategic importance of McGuinness' appointment as the company sharpens its focus on expanding commercial operations heading into 2026. Gappelberg explained that strengthening the sales organization is a critical pillar of Nextech3D.ai's growth strategy as demand continues to rise for its AI-powered 3D, spatial computing, and event technology solutions. McGuinness has been brought in to lead the company's global sales efforts, scale revenue-generating operations, and build a repeatable sales engine capable of supporting long-term growth. McGuinness brings more than 21 years of experience in enterprise and technology sales, with a proven track record of building and scaling sales teams at both early-stage startups and high-growth companies. Since joining Nextech3D.ai, he has already recruited two additional sales professionals, completing a fully staffed sales organization that blends long-tenured Nextech team members with experienced new hires. The company's current sales team now includes a senior sales leader with a decade of industry experience, five of which have been spent at Nextech; a sales assistant with five years at the company; a sales engineer with four years of tenure; an additional seasoned sales representative; and two junior sales representatives focused on pipeline development and account support. McGuinness' previous experience spans several well-known technology companies and successful exits. He was a founding salesperson for GeoTrust Europe prior to its acquisition by VeriSign, built and led sales development teams at SPSS Europe before its acquisition by IBM, and served as one of the founding salespeople at INXPO, an early pioneer in virtual event technology. He was also part of the founding sales team for LinkedIn Sales Navigator and played a key role in growing YCharts' revenue from approximately $1.6 million to roughly $20 million before the company's acquisition in 2020. Both Gappelberg and McGuinness emphasized that the strengthened sales leadership and fully built-out sales team position Nextech3D.ai to accelerate customer acquisition, deepen enterprise relationships, and capitalize on expanding market opportunities as the company moves into 2026. #nextech3d.al #otcqx #nexcf #cse #ntar #EvanGappelberg #ARway #AugmentedReality #SpatialMapping #IndoorNavigation #MapDynamics #EventTech #TradeShowSolutions #TechStocks #ARRevenueGrowth #3DTechnology #ProactiveInvestors #aws #amazonwebservice #tickets #kraftylab #jamesmcguinness

Medicus Pharma CEO Dr Raza Bokhari joined Steve Darling from Proactive to announce another major clinical milestone for the company, confirming that enrollment has been successfully completed in its Phase 2 clinical study evaluating the safety and efficacy of its Doxorubicin Microneedle Array (D-MNA), also known as SKNJCT-003, for the non-invasive treatment of nodular basal cell carcinoma (BCC) of the skin. The Phase 2 study has enrolled a total of 90 patients across nine clinical sites in the United States and is currently underway. Completion of enrollment represents a key step forward in Medicus Pharma's development strategy, positioning the company to advance discussions with regulators and accelerate progress toward later-stage trials. Dr. Bokhari explained that the company expects to report topline results from the SKNJCT-003 study in the first quarter of 2026. Following the release of these data, Medicus Pharma plans to pursue an end-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration in the first half of 2026 to discuss the next steps in the clinical and regulatory pathway. SKNJCT-003 is a randomized, double-blind, placebo-controlled, multi-center study designed to evaluate two dose levels of the Doxorubicin Microneedle Array compared with a placebo microneedle array (P-MNA). Participants are randomized on a 1:1:1 basis into three treatment arms: a placebo group receiving P-MNA, a low-dose group receiving 100 micrograms of D-MNA, and a high-dose group receiving 200 micrograms of D-MNA. The high-dose 200 microgram D-MNA represents the maximum dose previously tested in the company's Phase 1 safety and tolerability study, SKNJCT-001, which was successfully completed in March 2021. The Phase 2 trial builds on that foundation, aiming to further validate both safety and therapeutic effectiveness in a larger patient population. Medicus Pharma's microneedle-based approach is designed to deliver chemotherapy directly into skin lesions while avoiding the need for invasive surgery, offering the potential for improved patient comfort, cosmetic outcomes, and treatment accessibility. The successful completion of enrollment marks a critical inflection point as the company advances toward potential late-stage development and regulatory engagement. #proactiveinvestors #nasdaq #mdcx #tsxv #mdcx #pharma #Biotech #CancerTreatment #ClinicalTrials #FDAApproval #SkinCancer #HealthcareInnovation #Investing #MedicalResearch #SkinCancer #BasalCellCarcinoma #BiotechNews #CancerResearch #GorlinSyndrome #BasalCellCarcinoma #CompassionateUse #FDAApproval #RareDiseaseTreatment #NoninvasiveTherapy #BiotechNews

C3 Metals CEO Dan Symons joined Steve Darling from Proactive to announce highly encouraging results from the first drill hole ever completed at the company's Khaleesi copper project in southern Peru, marking a significant milestone for the greenfield exploration asset. The inaugural hole returned a broad intercept of 269.0 metres grading 0.30% copper, including a higher-grade interval of 60.4 metres at 0.41% copper starting from 346.0 metres downhole. Symons described the result as a strong validation of the geological model and a promising indication of scale for the emerging system. Khaleesi is currently being tested for the first time with an aggressive exploration program that includes two diamond drill rigs and a minimum of 6,000 metres of planned drilling. According to Symons, the early results point to the presence of a large, well-mineralized magnetite- and garnet-rich skarn body that is interfingered with multiple intrusive phases. The mineralized skarn–intrusive contact zone appears to be well defined, coinciding with strong chargeability and magnetic geophysical anomalies. Importantly, drilling has confirmed that copper mineralization extends beneath a broad area of shallow glacial till cover—an area that had not been previously drill-tested and which significantly expands the project's exploration footprint. Symons cautioned that additional drilling will be required before the ultimate size and geometry of the Khaleesi system can be determined. In the meantime, the company is collecting detailed geological, alteration, geochemical, and structural data from all drill holes. This information is being incorporated into a comprehensive 3D geological block model, which will be integrated with existing 3D geophysical datasets to refine targeting and guide future drilling. Based on the strong results from hole KHZ5800-001 and positive visual observations from additional holes that are either completed and awaiting assay results or currently being drilled, C3 Metals is actively considering expanding the drill program beyond the originally planned 14-hole, 6,300-metre campaign. The early success at Khaleesi underscores the project's potential to host a large-scale copper system and positions C3 Metals for continued exploration momentum as results continue to flow. #proactiveinvestors #c3metalsinc #tsxv #cccm #otcqb #cuauf #KhaleesiProject #CopperExplorat #PeruMining #GreenfieldExploration #DrillResults #CopperDiscovery #SkarnDeposit #BaseMetals #CriticalMinerals #MiningNews #ExplorationSuccess #DiamondDrilling #Geophysics #3DGeologicalModel #ResourceGrowth #CopperSupply #ProactiveInvestors

Blue Gold Limited CEO Andrew Cavaghan joined Steve Darling from Proactive to outline the company's latest strategic initiatives, highlighted by a major move into the rapidly emerging tokenized gold market. Cavaghan confirmed that Blue Gold Ltd has signed a landmark agreement securing access to 1 million ounces of gold, with an estimated value of approximately US$4.5 billion. The gold will underpin the company's planned tokenization strategy, allowing physical gold to be digitized and offered to the market as demand for gold-backed tokens grows. The supply agreement was established in partnership with DL Hudson Dunes, a long-established global commodities trading firm with operations spanning London, Singapore, and the United Arab Emirates. Cavaghan explained that the structure of the agreement provides flexibility, enabling Blue Gold to tokenize gold incrementally as market demand for the digital assets develops. In addition to the gold supply agreement, Cavaghan discussed Blue Gold's proprietary trading arrangements, which provide upstream access to gold sources. This structure has the potential to generate more attractive margins and strengthens the company's vertically integrated approach, combining physical gold exposure with innovative financial products. These strategic moves build on Blue Gold's Nasdaq listing in June 2025 and reflect the company's broader ambition to bridge traditional gold markets with the fast-evolving digital asset ecosystem. Cavaghan emphasized that tokenized gold offers investors the stability of a physical commodity with the accessibility and efficiency of blockchain-based assets. The interview also addressed Blue Gold's mining operations in Ghana, where the company owns the Focus Mine, which hosts a reported 5.1 million-ounce gold resource. Cavaghan confirmed that a legal dispute regarding the mine's title is ongoing. However, he noted that US$140 million has been placed in escrow and is available to restart production once the dispute is resolved. #proactiveinvestors #bluegoldlimited #nasdaq #bgl #GoldTokenization #BlueGoldLtd #DigitalAssets #GoldMining #TokenizedGold #AndrewCavaghan #CommodityTrading #NasdaqListing #GoldInvestment #DLHudsonDunes

Pathos Communications (LSE:NEWS) CEO Omar Hamdi talked with Proactive's Stephen Gunnion about the company's mission to revolutionise media access for small and medium-sized enterprises (SMEs) through its proprietary AI tools. Hamdi outlined how Pathos Communications solves a long-standing issue in the PR space: getting SMEs into mainstream media coverage, a space typically dominated by billion-pound companies. With over 400 million SMEs globally, the company aims to scale impact through technology, not traditional PR methods. Pathos, recently named the fastest-growing communications firm in the UK by the Financial Times, is now a London-listed business. Hamdi highlighted that the decision to list was strategic: “We looked at all of the markets in the world, and we said, London's the right place for us to be.” He also noted the rare backing of institutional investors, including Venture Capital Trusts. The firm's roadmap includes scaling existing systems, global expansion into non-English-speaking markets, and advancing two internal AI tools: PathosMind, a PR brain for agencies, and Pressella, a virtual publicist for SMEs. “We believe that every business should have a full-time publicist,” said Hamdi. “The good news is you don't have to pay $150,000 for one.” Watch the full interview for more on how Pathos plans to disrupt the global PR market. For more interviews, visit Proactive's YouTube channel. Don't forget to like this video, subscribe to our channel, and hit the bell for notifications on new content. #PathosCommunications #OmarHamdi #AIPR #PublicRelations #SmallBusinessMarketing #SMEGrowth #AItools #ProactiveInvestors #LondonIPO #TechGrowth #Pressella #PathosMind

Genflow Biosciences Ltd (LSE:GENF, OTCQB:GENFF) CEO Dr Eric Leire talked with Proactive's Stephen Gunnion about the company's progress in its canine gene therapy trial targeting sarcopenia. Leire confirmed that the dosing phase has now been completed with no adverse effects, calling it a key milestone in de-risking the SIRT6 programme for potential pharma partners and investors. He said, “We demonstrated some kind of safety, with the full dosing, we had to observe no side effect, no adverse side effect, even minor event.” Leire explained the study's scientific rigour, highlighting its randomised, controlled and blinded design using aged dogs not previously involved in clinical trials. This, he said, addresses a major unmet need in the life extension field, with industry experts previously considering such a study “impossible to do.” Looking ahead, efficacy data is expected in January, with analysis focused on multiple endpoints. These include mitochondrial function, clinical data, muscle biopsies, and epigenetic markers like the methylation clock in collaboration with UCLA. Leire said the results could influence other Genflow programmes, including preclinical work on NASH, Werner syndrome and ophthalmology. He noted that Genflow is in licensing discussions with several animal health companies and reiterated that while Genflow is not an animal health business, a potential deal could be shaped by the strength of the efficacy data. Visit Proactive's YouTube channel for more exclusive interviews. Don't forget to like this video, subscribe to the channel, and turn on notifications so you never miss an update. #GenflowBiosciences #SIRT6 #GeneTherapy #Sarcopenia #LifeExtension #CanineTrial #BiotechNews #PharmaDeals #AgeingResearch #BiotechInvesting #ClinicalTrials #MitochondrialFunction #BiotechUpdate #ProactiveInvestors

HIVE Digital Technologies (TSX-V:HIVE, NASDAQ:HIVE) executive chairman Frank Holmes talked with Proactive's Stephen Gunnion about the company's progress in both its Bitcoin mining operations and AI HPC initiatives. Holmes highlighted that the company has scaled its Bitcoin hash rate from 6 to 25 exahash over six months, a significant milestone that brings increased stability and improved margins. “We've hit that critical mass event where we have more stability and margins,” he said. He also noted the strategic benefit of sourcing only green energy, with HIVE supporting Paraguay's infrastructure through the development of substations and employing local engineers. In November, the company mined 290 Bitcoin, representing an 8% increase month over month and a 180% increase year over year. Holmes positioned this performance as superior to Bitcoin's price performance and that of peers in the sector. On the AI side, HIVE is seeing strong growth. Revenue has doubled in the past year and is expected to grow 5 to 6 times over the next 12 months. Holmes attributed this to the delivery of more Nvidia chips to data centers and a partnership with Bell Canada. He said the company is aiming for up to $140 million in AI-related revenue, with 10,000 clients worldwide already using or renting its services. Looking to 2026, HIVE plans to grow from 25 Eh to 35 Eh, with the Paraguayan government granting another 100MW of electricity. The company believes this could eventually expand to one gigawatt. Meanwhile, HIVE is repurposing a Bitcoin data center in Sweden into a high-performance computing hub, and sees strong potential at a site in New Brunswick, Canada. For more updates from leaders in crypto and tech, visit Proactive's YouTube channel. Don't forget to like the video, subscribe to the channel, and turn on notifications so you never miss an update. #HIVEDigital #BitcoinMining #AIHPC #CryptoInvesting #GreenEnergy #ParaguayMining #NvidiaChips #DataCenters #BlockchainTechnology #HighPerformanceComputing #CryptoNews #ProactiveInvestors

Pinnacle Silver & Gold Corp (TSX-V:PINN, OTCQB:PSGCF) CEO Robert Archer talked with Proactive's Stephen Gunnion about the company's first drill program at the El Potrero project in Mexico, which will start with underground drilling rather than surface work. Archer explained that the underground access available at El Potrero, due to historic mining that ceased 35 years ago, gives the company immediate access to mineralized zones. However, he pointed out the current workings are limited in extent, and only sampling what's visible on the walls and ceilings leaves uncertainty about the broader potential. He emphasized that, “you want to be able to blend the high grade and the low grade, such that you have a fairly consistent grade going to the plant,” highlighting the importance of understanding grade variability and distribution through drilling. This 112-hole delineation program will target three known zones within historic mines, while still leaving key areas between the mines and additional veins for future surface exploration. The underground results will contribute to a preliminary mine plan, including potential head grades and mining approaches. Looking ahead, a surface drill program will follow to explore other veins such as El Capulin, La Estrella, and Dos de Mayo, which have not been drilled previously. Visit Proactive's YouTube channel for more exclusive interviews and updates. Don't forget to like this video, subscribe to the channel, and hit the bell for notifications on future content. #PinnacleSilver #GoldExploration #SilverMining #ElPotrero #MiningMexico #JuniorMining #UndergroundDrilling #MiningStocks #NaturalResources #PreciousMetals

RenoWorks Software Inc (TSX-V:RW, OTC:ROWKF) CEO Doug Vickerson talked with Proactive's Stephen Gunnion about the company's continued growth and investment focus as it expands its AI-powered home design platform. Vickerson outlined how RenoWorks is helping users, including homeowners, contractors, and manufacturers, virtually remodel their homes using real manufactured products. He explained that answering the question "What will my remodel project look like when it's done?" is at the core of their offering. The company has shifted its focus in recent years to grow its licensing and hosting revenues, with the goal of increasing annual recurring revenue (ARR). “We made some significant investment in our product platform… and we're starting to see that come to fruition now,” Vickerson said. He highlighted consistent growth in licensing revenues over the last three quarters, noting that Q3 results showed strong gains alongside margin improvements. On the innovation front, RenoWorks has been leveraging AI for more than six years. Vickerson said that while AI terminology is widespread today, RenoWorks has long used machine learning, and new advances are enabling what he called “revolutionary” enhancements in design software. The company is working to simplify AI adoption for its customers, especially in exterior renovations, by offering tailored tools for the industry. Looking ahead to 2026, the company plans to maintain its focus on ARR growth and on enhancing product functionality using the latest AI developments. Visit Proactive's YouTube channel for more videos, and don't forget to give the video a like, subscribe to the channel and enable notifications for future content. #RenoWorks #HomeRenovationTech #AIDesignTools #RemodelingSoftware #ARRGrowth #DougVickerson #RenovationVisualization #ConstructionTech #PropTech #ProactiveInvestors

OS Therapies Inc (NYSE-A:OSTX) chief business officer Gerald Commissiong talked with Proactive's Stephen Gunnion about the company's recent regulatory progress for its OST-HER2 immunotherapy platform targeting osteosarcoma. Commissiong detailed how OS Therapies acquired rights to a listeria-based therapy originally developed by Advaxis and how this technology has evolved into a precision platform targeting HER2-expressing cancers. The OST-HER2 approach uses attenuated listeria engineered to infect cancer cells, triggering a robust immune response. “Basically, once infected with the listeria, our vector releases additional cancer antigens,” Commissiong explained, noting how this mechanism amplifies immune activity via T cells, NK cells, and dendritic cells. He outlined progress with regulators, including a Type C meeting with the FDA, pre-marketing discussions with the MHRA in the UK, and a meeting with the European CHMP. “The tenor of those conversations… is around trying to find a pathway to get this drug into patients' hands sooner,” he said, adding that discussions included using historical control data and biomarkers as surrogate endpoints for accelerated approval. Commissiong also revealed the broader pipeline, including constructs targeting HPV-driven cancers and prostate cancer. Key next steps include biomarker analysis and initiation of a confirmatory study. Visit Proactive's YouTube channel for more biotech and pharma interviews. Don't forget to like this video, subscribe to the channel, and enable notifications for future content. #OSTHER2 #OSTherapies #Osteosarcoma #CancerImmunotherapy #FDAapproval #Biotech #ListeriaTherapy #CancerResearch #AcceleratedApproval #OncologyInnovation #HPVcancer #ProstateCancer #MHRA #CHMP

Greengage & Co Group Plc founder and CEO Sean Kiernan talked with Proactive's Stephen Gunnion about the company's plans to float on the Access segment of the Aquis Growth Market and its unique Bitcoin yield reserve strategy. Kiernan explained how Greengage, a fintech platform offering accounts and lending services, is addressing challenges faced by clients in the crypto space and underserved SMEs. The platform facilitates wholesale Bitcoin-backed loans and focuses on private credit lending. He highlighted the company's differentiated treasury approach, stating, “Our version is using our own fintech platform... to get a loan against Bitcoin... and then deploy out the loan proceeds to the private credit world.” The strategy seeks to earn a net yield by leveraging Bitcoin through lending, while protecting downside risk using structured loan mechanisms. Kiernan also shared details about the IPO plans, noting the decision to list on Aquis was driven by strong liquidity in the Bitcoin treasury space. Proceeds from the IPO will largely be used to acquire Bitcoin, which will then be leveraged to fund yield-generating loans. With over 40 client accounts opened and more than $350 million in loans facilitated to date, Kiernan sees significant growth potential. He said the IPO will help build awareness of the core fintech platform and increase investor engagement, while reinforcing the company's strategic focus on Bitcoin as a treasury asset. To hear more about Greengage's growth plans and strategy, watch the full interview. For more videos like this, visit Proactive's YouTube channel. Don't forget to give this video a like, subscribe, and turn on notifications to stay updated. #BitcoinYield #CryptoLending #GreengageGroup #SeanKiernan #FintechStrategy #AquisIPO #BitcoinTreasury #PrivateCredit #DeBanking #Stablecoins #CryptoFinance #IPO2025 #DigitalAssets #BlockchainFinance #BitcoinLoans

Great Southern Copper PLC (LSE:GSCU) chief executive Sam Garrett talked with Proactive's Stephen Gunnion about the latest high-grade drilling results at the Cerro Negro project, with a focus on the Mostaza target area. Garrett said recent intercepts confirmed the presence of stacked lenses, potentially increasing the size and value of the copper-silver system. “The realisation in the recent drilling of the potential for stacked lenses is clearly going to give us the opportunity to expand the potential size of this deposit,” he explained. Metallurgical testing is underway to determine copper and silver recovery rates, which will enable the company to report results in copper or silver equivalents. Garrett said this will offer clearer comparisons with other assets in the sector. He also highlighted progress at the Viuda Negra prospect, where early drilling indicates a potentially large Maricunga-style gold porphyry system, significant as such systems have not previously been recognised in Chile's coastal belt. While early gold grades were low, Garrett noted economic grades were intersected in mineralised porphyry zones. The company recently raised £2.5 million to fund expanded drilling at Especularita, with three rigs now active. Investors can expect news flow from ongoing drilling, further metallurgical updates, and planning for phase four drilling at Mostaza, as well as continued exploration at Viuda Negra and scout drilling across the broader Especularita region. For more interviews and updates from the mining and exploration sector, visit Proactive's YouTube channel. Don't forget to like the video, subscribe, and turn on notifications. #CopperExploration #SilverMining #GoldDiscovery #ViudaNegra #CerroNegro #MostazaDrilling #MetallurgyTesting #JuniorMining #ChileMining #MiningNews #NaturalResources #GreatSouthernCopper #ProactiveInvestors

Chariot Ltd (AIM:CHAR, OTC:OIGLF) chief financial officer Julian Maurice-Williams talked with Proactive's Stephen Gunnion about two key announcements tied to the company's renewable energy operations in South Africa. The first announcement covers the financial close of two large-scale wind power projects — Zen (100MW) and Bergriver (94MW) — both located in the Western Cape. Maurice-Williams highlighted that Chariot Generation and Trading, a new subsidiary, owns 24% of the assets alongside project lead Acciona Energía. Construction is set to begin imminently, with commissioning targeted for mid-2027. The second announcement focuses on the financing of Chariot's stake. Maurice-Williams explained the multi-layered structure, stating: “We brought in a strategic partner, and we've done it all at the subsidiary level… around $100 million net.” Funding sources include $284 million of project finance debt from Standard Bank and Investec, a $17 million equity investment from South African fund Mahlako, and a $9 million mezzanine facility from Standard Bank. He also outlined how the structure ensures no dilution at the parent level, while retaining control of the renewable business. Looking ahead to 2026, Chariot aims to generate material revenues from both its renewable and upstream oil and gas arms. Maurice-Williams also noted that the company is exploring the separation of these divisions and has entered discussions with ACWA Power regarding a broader Southern African sustainable energy platform. Visit Proactive's YouTube channel for more company interviews. Don't forget to like the video, subscribe, and enable notifications for future updates. #ChariotLtd #RenewableEnergy #WindPower #SouthAfricaEnergy #EnergyTransition #ProjectFinance #ElectricityTrading #CleanEnergy #JulianMauriceWilliams #ProactiveInvestors #EnergyInvestment #ACWAPower

S&U PLC (LSE:SUS) chairman Anthony Coombs talked with Proactive's Stephen Gunnion about the company's strong growth in the third quarter of 2025 and the outlook for 2026, particularly across its Advantage and Aspen businesses. Coombs said he expects further momentum in 2026, even if the broader economy remains flat, due to increasing market share and the company's operational improvements. He highlighted the recent performance of Advantage, the group's motor finance division, which has seen “record collection rates” and strong loan quality following industry-wide challenges and regulatory scrutiny. “We've been trading our socks off for the last 3 or 4 months,” Coombs said, noting the investigation by the FCA is now complete and has confirmed the company's compliance. Risk management remains a key focus. Coombs explained that S&U has improved its affordability assessments and credit scoring systems to ensure sustainable growth. The company is also introducing AI to support greater efficiency and customer onboarding. Discussing funding, he confirmed that net borrowings have risen in line with growth, and longer-term funding options such as securitisation are being explored. Looking ahead to 2026, Coombs said, “Actually, I see the economy slightly picking up in 2026. But even if it doesn't, we're going to be taking more market share.” For more interviews like this, visit Proactive's YouTube channel. Don't forget to like this video, subscribe, and enable notifications for future updates. #MotorFinance #SAndUPLC #AnthonyCoombs #AdvantageFinance #AspenBridging #2026Outlook #FinanceGrowth #AutoLoans #BridgingFinance #ProactiveInvestors

Geomega Resources (TSX-V:GMA) CEO Kiril Mugerman talked with Proactive's Stephen Gunnion about the company's bauxite residue technology and its potential global impact. In the interview, Mugerman explained how Geomega is addressing the 200 million tonnes of bauxite residue generated annually, with over 4.5 billion tonnes currently stored globally. He detailed the company's clean technology solution designed to convert this industrial waste into value. "This is a technology for bauxite residues," Mugerman said, describing how the waste, which results from aluminum refining, can be treated instead of being left to accumulate in storage ponds. Mugerman highlighted Geomega's joint development agreement with Rio Tinto, valued at C$4.5 million, to build a demonstration plant in Saguenay, Quebec. Although the timeline is controlled by Rio Tinto, the goal is to complete the project within approximately two years. The CEO also spoke about presenting bench-scale results in China, which demonstrated over 90% residue volume reduction and successful performance across six different bauxite residue sources. The next step is to scale to a demonstration plant. “A major company gave the green light to do the next scale up, which is exciting,” he noted. Mugerman also emphasized the role of government support in advancing the technology readiness level, helping position Geomega for future commercial agreements. For more interviews, visit Proactive's YouTube channel. Don't forget to like the video, subscribe, and enable notifications for future updates. #GeomegaResources #BauxiteResidue #CleanTech #RioTinto #AluminiumRecycling #WasteToValue #CriticalMinerals #SustainableMining #GreenTechnology #CanadaMining

Sintana Energy CEO Robert Bose joined Steve Darling from Proactive to discuss the company's progress on two major fronts: the advancement of its acquisition of Challenger and new developments across key blocks in Namibia's Orange Basin. Bose reported that the planned acquisition of Challenger has now satisfied several significant conditions, including formal consent from ANCAP—Uruguay's national hydrocarbon regulator—and confirmation from Chevron indicating no objection to the transaction. With these milestones achieved, the deal now only requires final approval from the TSX Venture Exchange. A Court Sanction Hearing, originally delayed following later-than-expected ANCAP approval, has been rescheduled for December 12. On 26 November 2025, Challenger confirmed that the Scheme of Arrangement received strong shareholder backing, with the requisite majorities approving both the Scheme at the Court Meeting and the related Special Resolution at the General Meeting. Pending court sanction, registration of the Court Order, and satisfaction or waiver of remaining conditions outlined in the Scheme Document, the transaction is expected to become effective on 16 December 2025. Bose also provided an important operational update on Blocks 2813A and 2814B in Namibia's Orange Basin—one of the world's most closely watched offshore exploration regions. The blocks fall under Petroleum Exploration License 83 (PEL 83), currently operated by a subsidiary of Galp. Sintana maintains an indirect 49% interest in Custos Energy, which itself holds a 10% working interest in PEL 83, giving Sintana an effective 4.9% carried interest. NAMCOR, Namibia's state energy company, holds an additional 10% working interest. Major structural changes are underway at the asset level. TotalEnergies and Galp have agreed to a transaction that will see TotalEnergies assume operatorship of PEL 83 and secure a 40% participating interest from Galp, which presently owns 80%. As part of the agreement, the parties will initiate a multi-well exploration and appraisal campaign over the next two years, targeting at least three wells aimed at further de-risking the block and defining a potential first development hub within the acreage. The first exploration well under this new program is currently being assessed for potential drilling in 2026—positioning PEL 83 as a key contributor to the growing momentum in the Orange Basin and reinforcing Sintana's strategic exposure to one of the most prolific emerging petroleum regions globally. #proactiveinvestors #sintanaenergyinc #tsxv #sei #otcqb #seusf #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews #OilExploration #Namibia #OrangeBasin #EnergySector #PEL83 #RobertBose #GalpEnergia #Chevron #QatarEnergy #EnergyNews #ProactiveInvestors #2025EnergyTrends

Aftermath Silver CEO Ralph Rushton joined Steve Darling from Proactive to announce the commencement of a new, targeted follow-up drilling campaign at the company's flagship Berenguela silver-copper-manganese project in southern Peru. The program includes approximately 4,000 metres of diamond core drilling and 2,000 metres of reverse circulation (RC) drilling, marking a significant new phase of exploration aimed at further enhancing the project's resource potential. Rushton explained that drilling is also set to begin this week at Aftermath Silver's Challacollo silver-gold project in Region I of northern Chile. At Challacollo, the company plans to complete between 1,000 and 2,000 metres of core drilling as it advances its exploration strategy across multiple high-priority assets. The decision to accelerate drilling activity reflects both favourable market conditions and strong technical confidence in the projects. Rushton noted that with silver prices currently at elevated levels, the company believes now is the optimal time to advance both exploration and resource growth. At Berenguela, the focus of the program will be on following up high copper grades previously encountered on the eastern side of the existing resource. In addition, infill drilling will target areas believed to represent the most likely location for initial future mining operations. Rushton emphasized that the campaign is designed not only to expand and upgrade known mineralization but also to support longer-term development planning by improving geological confidence in critical zones of the deposit. With two active drill programs underway in Peru and Chile, Aftermath Silver is positioning itself to capitalize on strong metals markets while advancing its portfolio of advanced-stage silver projects. #proactiveinvestors #aftermathsilverltd #tsxv #aag #otcqx #aagff #mining #SilverMining, #BerenguelaProject, #Mining #Silver #Copper #Manganese #Peru #DrillingResults #BatteryMetals #ResourceModel #Investing

Delta Gold Technologies PLC (AQSE:DGQ) CEO Michael Jones joined Stephen Gunnion in the Proactive studio to discuss more about the company's innovative approach to quantum computing, underpinned by its nanoscale gold-based technology. Jones explained that while many firms claim to have quantum computers, the core challenge of creating stable and scalable qubits remains unresolved. Delta Gold is focused on a novel method using nanoscale gold to address this challenge, backed by a leading research partnership with the University of Toronto. “The power of the quantum computer is something that can cross a whole bunch of different sectors, and that gives us a lot of opportunity to look for partners or licensees to our technology,” Jones said. He highlighted the company's relationship with Professor Harry Ruda, a globally cited expert who leads Delta Gold's research efforts, and noted the significant advantage of working within a university ecosystem. Delta Gold has recently listed on the Aquis Stock Exchange, with a market cap now exceeding £10 million following a 50% rise post-IPO. Capital raised will fund a three-year research programme, with IP development and patent filings planned. Jones confirmed that major stockholders are locked in, reflecting strong confidence in the company's long-term potential. For more interviews like this, visit Proactive's YouTube channel. Don't forget to like the video, subscribe, and turn on notifications to stay updated. #QuantumComputing #DeltaGoldTechnologies #MichaelJones #Qubits #UniversityOfToronto #QuantumResearch #AquisStockExchange #TechInvestment #QuantumIP #EarlyStageTech #GoldInQuantum

Ilika PLC (AIM:IKA, OTCQX:ILIKF) CEO Graeme Purdy talked with Proactive's Stephen Gunnion about a significant milestone for the company as it successfully shipped its 10Ah Goliath battery prototypes on schedule. Purdy noted that the delivery reflects the company's commitment to meeting expectations and keeping to its timelines. The prototypes will now be evaluated by customers, with Ilika expecting collaborative feedback to further refine its solid-state battery technology. Purdy explained that the next key milestone is the development of a 50Ah cell and that licensing discussions are already underway. He emphasised Ilika's asset-light model, saying that the company does not intend to build large factories itself but will rely on technology transfer and partners to scale up. Ilika's pilot line has achieved a 93% yield, which Purdy described as a “really great validation that we have a robust process that is ready for scale up.” This result exceeds typical expectations at this stage and supports the transition towards commercialisation. The interview also touched on Ilika's modelling work with Balance Batteries Ltd, which demonstrated potential cost and performance benefits for EV applications. The company claims a 20% reduction in battery pack costs and a corresponding increase in vehicle range when using its technology. To conclude, Purdy shared that further updates may follow from Ilika's Stereax product line as the year closes, with half-year results expected in early 2026. For more interviews and insights, visit Proactive's YouTube channel. Don't forget to like the video, subscribe, and enable notifications to stay up to date. #IlikaPLC #SolidStateBatteries #EVTechnology #BatteryInnovation #CleanEnergy #GoliathBattery #Stereax #TechTransfer #BatteryPrototypes #PilotLine #EnergyStorage #ProactiveInvestors

Fineqia International Inc (CSE:FNQ) senior associate Matteo Greco talked with Proactive's Stephen Gunnion about the key takeaways from the firm's November report on crypto exchange-traded products (ETPs), which tracked a 17% drop in crypto assets – closely aligned with a broader 16% market decline. Despite the downturn, Greco noted that outflows from ETPs were minimal, indicating growing maturity and long-term investor confidence in crypto-backed financial products. “This is a strong vehicle to get exposure to the asset class,” Greco said, emphasizing the resilience of the crypto ETP market. He highlighted that Bitcoin ETPs saw only $3 billion in outflows despite a 17.5% price drop, suggesting that investors in these products tend to have a longer investment horizon. Similarly, while Ethereum ETPs recorded their first monthly outflows after seven months of inflows, Greco said that, proportional to market cap, Ethereum has attracted relatively stronger demand than Bitcoin. Regarding altcoin ETPs, Greco pointed to a positive trend driven by recent US ETF approvals for assets like Solana and Dogecoin. He added that the broader range of products could signal the early signs of an "alt season." Looking ahead, Greco believes the launch of over 300 listed crypto ETPs indicates sustained institutional interest heading into 2026. For more expert insights like this, visit Proactive's YouTube channel. Don't forget to like this video, subscribe to the channel, and enable notifications for future content. #CryptoETPs #Fineqia #BitcoinETP #EthereumETP #Altcoins #CryptoInvesting #ETFs #InstitutionalCrypto #CryptoMarkets #ProactiveInvestors

Optima Health PLC (AIM:OPT) chief executive Jonathan Thomas talked with Proactive's Stephen Gunnion about the company's strong first half performance, posting 17% revenue growth. Thomas credited both organic expansion and recent M&A activity, including the acquisitions of Cognate Health in Ireland and Care first, as key contributors. “The market backdrop is really good. There's great demand for our services. We're winning new business, and we anticipate to continue to grow,” said Thomas. He outlined how Cognate Health has now been rebranded as Optima Health Ireland, with the company beginning to leverage revenue synergies across jurisdictions. Care first, which complements Optima's existing EAP and mental health operations, is expected to complete its integration in Q4 of the current financial year. Thomas also discussed the company's operational transformation programme, which is designed to improve margins and scale effectively as growth continues. This includes clinical enhancements, automating processes, and optimising central support functions. The interview also touched on Optima's £210 million UK Armed Forces contract, now being mobilised, and £8.3 million of new business either signed or at preferred bidder stage—positioning the company for growth into FY27 and FY28. Looking ahead, Thomas reaffirmed the company's target of reaching £200 million in revenue and £40 million EBITDA, driven by organic growth, operational efficiency, and further M&A. For more interviews like this, visit Proactive's YouTube channel. Don't forget to like this video, subscribe to the channel, and turn on notifications for future updates. #OptimaHealth #HealthcareStocks #EarningsUpdate #MergersAndAcquisitions #OperationalTransformation #MentalHealthServices #HealthcareUK #RevenueGrowth #EBITDA #ProactiveInvestors

MustGrow Biologics Corp Chief Operating Officer Colin Bletsky joined Steve Darling from Proactive to announce outstanding performance results for the company's organic TerraSante™ biofertility product, based on large-scale customer performance data from commercial potato operations in Washington State and Idaho. The results demonstrate meaningful improvements in crop yield, size, and overall quality when TerraSante™ is incorporated into existing grower production programs. Bletsky told Proactive that one Washington State farming customer recorded consistent and substantial improvements in potato yield, tuber size, and crop quality using TerraSante™ at a dose rate of 11 pounds per acre. The performance data was generated on a large commercial potato field, providing a real-world validation of the product's effectiveness at scale. Based on the improved size, quality, and yield of the crop, the farmer estimated an approximate increase in revenue of US$5,000 per acre, achieved at a product cost of just US$180 per acre for TerraSante™. Additional work completed across potato fields in Idaho has also demonstrated significant agronomic benefits. These trials showed measurable improvements to both soil health and crop vigor when TerraSante™ was applied within growers' existing production programs, reinforcing the product's versatility and compatibility with established farming practices. TerraSante™ is a mustard-derived, organic biofertilizer formulated as a soluble, mixable product containing nutritious plant proteins and carbohydrates. These inputs are designed to feed both the soil and beneficial soil microbes, helping to improve soil biology, nutrient availability, and overall plant performance in a sustainable manner. The product is currently registered and approved for sale in six key U.S. agricultural states California, Florida, Arizona, Idaho, Oregon, and Washington. TerraSanteTM is also certified under the Organic Materials Review Institute (OMRI) Listed® program and California's Organic Input Material (OIM) Program, allowing it to be used in certified organic farming operations. Bletsky noted that the strong commercial performance data further supports MustGrow's strategy to commercialize sustainable, high-performance biological solutions that deliver both environmental benefits and compelling economic returns for growers. #proactiveinvestors #mustgrowbiologicscorp #tsxv #mgro #otcqb #mgrof #mustardseed #TerraSante #Biofertility #AgricultureTechnology #SustainableFarming #OrganicFarming #CropEnhancement #SoilHealth #AgriBusiness #ProductDistribution #florida #grapefruit #bellpeppers #watermelons #tomatos

Temas Resources CEO Tim Fernback joined Steve Darling from Proactive to provide an update on the continued advancement of the company's La Blache Property in Quebec, along with significant progress on its proprietary metallurgical technology initiatives. Fernback outlined Temas' unique dual-business model, explaining that the company operates both as a metallurgical technology developer and as an advancing critical minerals exploration and development company focused on titanium, vanadium, and iron. Fernback noted that Temas has completed approximately 45,000 metres of drilling at the La Blache Property to date, establishing a substantial geological database for the project. He highlighted that the company has already delivered a Preliminary Economic Assessment (PEA), which demonstrates the scale and strength of the asset. The PEA indicates approximately $6.6 billion of in-situ rock value underground with an internal rate of return (IRR) of over 60%, underscoring the project's robust economic potential. A key component of Temas' strategy is its proprietary regenerative chloride leach (RCL) platform technology. Fernback explained that the RCL system is designed to extract metals from complex mineralized rock while recycling reagents within a closed-loop process. By reusing key inputs, the technology is engineered to significantly reduce both operating costs and energy consumption compared to conventional processing methods. According to Fernback, the RCL platform can deliver approximately 65% savings versus traditional metallurgical approaches, positioning it as a potentially disruptive solution for the global mining and processing industry. Temas is actively evaluating international licensing and joint venture opportunities for the RCL technology, as the company looks to commercialize the platform beyond its own projects and create an additional revenue stream independent of mining operations. The interview also highlighted the company's recently completed 2,300-metre drilling program at La Blache, with assay results expected in early 2026. Fernback added that planned work in the coming year includes advancing both the La Blache and Lac Brûlé projects toward feasibility-stage studies, while continuing to strengthen the company's metallurgical division and expand its technology footprint. Fernback also pointed to the company's recently completed Australian initial public offering, which successfully raised $11.00 million. He said the financing leaves Temas fully funded for its upcoming work programs, positioning the company to execute on both its project development and technology growth strategies without near-term funding constraints. #proactiveinvestors #temasresourcescorp #asx #tio #cse #tmas #otcqb #tmasf #LaBlacheProject #MiningNews #CriticalMinerals #Titanium #Vanadium #IronOre #MetallurgicalTechnology #RCLTechnology #QuebecMining #ResourceStocks #DrillingUpdate #2026Outlook

Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF) CEO Phillip L'Huillier talked with Proactive's Stephen Gunnion about new clinical data from its phase two melanoma study, known as the SCOPE trial, featuring its lead ImmunoBody candidate, iSCIB1+. L'Huillier highlighted that the trial has achieved the objectives set out for it, confirming the parameters for the company's upcoming registrational phase three study. The findings now provide clarity on dosing, patient population, and trial design. “Our SCOPE study…has met the objectives that we set out for it,” he said. A key point of the discussion focused on the data, which showed a 74% progression-free survival rate at 16 months for iSCIB1+. This compares to 46% at 12 months for the standard of care, which typically includes dual checkpoint inhibitors Ipilimumab and Nivolumab. L'Huillier noted this as a "really strong and durable benefit" on top of existing treatments. He also addressed how iSCIB1+ performed across patient subgroups where existing therapies are typically less effective—such as BRAF, PD-L1 status, and those with prior checkpoint treatment—with results showing clinically meaningful benefit across all. Scancell now plans to begin its phase three trial in late 2026, having received supportive regulatory feedback. L'Huillier also said the data has materially strengthened the company's case for partnering and financing opportunities as part of a dual-track strategy to either partner or proceed independently. Watch the full video for more insights. Like, subscribe, and enable notifications so you never miss an update from Proactive's YouTube channel. #Scancell #Melanoma #CancerResearch #ClinicalTrials #Immunotherapy #iSCIB1 #BiotechNews #Phase3Trial #Oncology #ProactiveInvestors

Australian Oil Company Limited (ASX:AOK) managing director Kane Marshall talked with Proactive's Stephen Gunnion about the company's diversified strategy across gas and oil markets in both the United States and Australia. Marshall outlined the company's expansion in the Sacramento Basin in California, where it has increased its working interest without a cash outlay. He noted that this consolidation gives the company greater control and positions it well amid rising demand for energy from data centres and critical industries. “We sort of can dictate our own terms, so to speak,” he said, referring to the advantages of consolidation amid recent mergers in the US sector. In Australia, the company has secured a strategic package in Queensland's Surat Basin, including producing fields, 3D seismic coverage, and nearby pipeline infrastructure. Marshall pointed out that gas prices remain attractive and that the assets are near a refinery selling oil at AU$100 a barrel, making the economics "extremely attractive". Marshall emphasised that both the US and Australian markets are “hungry for gas” and the company is delivering on its stated goals by entering these regions. He said the company remains focused on deploying capital into the highest-impact projects and hinted at upcoming exploration efforts in both jurisdictions. As the company heads into 2026, investors can expect updates on drilling prospects and production increases, particularly in Queensland. Marshall also referenced other active operators in the area and sees further corporate activity as likely. Visit Proactive's YouTube channel for more interviews like this. Don't forget to like the video, subscribe, and turn on notifications so you never miss an update. #AustralianOilCompany #OilAndGas #KaneMarshall #SuratBasin #SacramentoBasin #NaturalGas #EnergyInvesting #AussieEnergy #DataCenters #EnergyInfrastructure #CaliforniaGas #QueenslandGas #OilExploration #InvestorUpdates #ProactiveInvestors

Jupiter Asset Management lead investment manager Tarlock Randhawa joined Stephen Gunnion the Proactive studio to discuss the investment case for global smaller companies included in the Jupiter Origin Global Smaller Companies Active UCITS ETF (JOGS) and the approach taken by the Jupiter Origin team. Randhawa outlined the structural advantages of investing in small caps, noting their potential for price appreciation and under-researched nature. "We certainly think that there is a larger opportunity of potential price appreciation in the small-cap space," he said, pointing to the wider universe of opportunities relative to large-cap benchmarks. He explained that small caps offer more potential upside but come with higher stock-specific risks. To mitigate this, the team diversifies across around 200 names per portfolio. Randhawa also highlighted that the team seeks companies with a proven history of wealth creation, strong future profitability expectations, and attractive valuations. The Jupiter Origin strategy is built on a rigorous, evidence-based screening process. Starting with a universe of 5,000 stocks, the team applies a mechanical filter based on metrics they believe will lead to outperformance. The final portfolio has over 90% active share compared to the benchmark. While macroeconomic conditions do not drive the team's decisions, Randhawa acknowledged that the current environment — particularly falling interest rates and valuation gaps between small and large caps — is supportive for smaller companies. Discussing the team's background, he noted that the core members have worked together for 25 years, with 15 years of experience in global small caps. The team of five maintains a disciplined, collaborative process to reduce behavioural biases and maintain consistency in strategy execution. For more insightful interviews, visit Proactive's YouTube channel. Don't forget to like the video, subscribe to our channel, and enable notifications to stay updated. #JupiterAssetManagement #GlobalSmallCaps #SmallCapInvesting #TarlockRandhawa #JupiterOrigin #EquityMarkets #StockPicking #InvestmentStrategy #ActiveManagement #InterestRates #PortfolioManagement #ValuationGap

Millennial Potash Chairman Farhad Abasov joined Steve Darling from Proactive to discuss the global potash supply landscape and the company's continued progress on its flagship potash project in Gabon. Abasov highlighted the strategic importance of potash as a critical input for global food security and underscored the vulnerabilities faced by countries that rely heavily on imports. Abasov noted that the United States currently imports approximately 97% of its potash requirements, with the majority coming from Canada and smaller volumes sourced from Russia and other regions. “If we're talking about food security and diversifying critical minerals supply chains, then potash specifically is one of the most important things,” he said, emphasizing the geopolitical and economic risks tied to concentrated global supply. He explained that Millennial Potash's project in Gabon is uniquely positioned along the Atlantic coast, providing significant logistical and economic advantages. The project's proximity to deep-water port infrastructure allows for efficient export to major agricultural markets, including the United States, Brazil, and across Africa. Abasov added that the project's low-cost structure and favorable geography place the company in a strong competitive position within the global potash market. Abasov also discussed broader trends impacting the fertilizer industry, including rising global demand and the increasing difficulty of developing large-scale potash projects. He referenced recent budget overruns at major industry developments, including those reported by BHP, as evidence of escalating capital costs across the sector. In contrast, he noted that Millennial Potash's use of solution mining technology materially reduces both capital intensity and environmental impact compared with conventional underground mining methods. The company has now formally initiated its Environmental and Social Impact Assessment (ESIA), marking a key transition from exploration into the development phase of the project. Abasov confirmed that the ESIA will be conducted in accordance with International Finance Corporation (IFC) Performance Standards and will serve as a critical component of Millennial Potash's future mining application. With global fertilizer markets under pressure, supply chains tightening, and food security emerging as a growing strategic priority, Abasov said Millennial Potash is advancing its Gabon project at a time when new, sustainable potash supply is increasingly vital to global agriculture. #proactiveinvestors #millennialpotahscorp #tsxv #mlp #otcqb #mlpnf #potash #CriticalMinerals #Potash #USGeologicalSurvey #FertilizerIndustry #USDFC #FoodSecurity #ResourceEstimates #MiningNews #GabonProjects #ProactiveInvestors

Nextech3D.ai CEO Evan Gappelberg joined Steve Darling from Proactive to announce that the company has signed a definitive agreement to acquire KraftyLabs, an AI-powered virtual and in-person event engagement platform serving a global enterprise client base. KraftyLabs' customers include major technology and multinational brands such as Google, Netflix, Meta, Oracle, Microsoft, Cisco, Dropbox, and more than 400 additional Fortune 500 and international companies. The two companies have now entered a formal due diligence and integration phase, with the transaction expected to close in the first week of January 2026. Gappelberg told Proactive that KraftyLabs has generated more than US$1.1 million in revenue year-to-date, reflecting strong demand for its enterprise-focused engagement solutions. The company specializes in delivering immersive virtual team-building experiences, leadership development sessions, corporate training programs, employee wellness initiatives, and cross-cultural learning formats for distributed global workforces. More recently, KraftyLabs expanded into in-person enterprise events, opening a new high-growth segment alongside its established virtual and hybrid offerings. With the addition of KraftyLabs, alongside Nextech3D.ai's existing acquisitions of Map Dynamics and Eventdex, the company now supports more than 1,000 customers worldwide. The expanded client roster includes many of the world's largest and most recognizable brands, significantly strengthening Nextech3D.ai's enterprise footprint and recurring revenue potential. Gappelberg said the KraftyLabs acquisition is a strategic step in Nextech3D.ai's broader vision to create a fully unified, AI-driven event ecosystem. Once integrated, the combined platform is expected to become what the company believes will be the most advanced and innovative end-to-end AI Event Solution available in the market. The consolidated offering will be capable of powering virtual, in-person, hybrid, and large-scale enterprise events through a single, unified technology stack. The acquisition positions Nextech3D.ai to capitalize on accelerating global demand for intelligent event platforms that enhance engagement, improve data analytics, and streamline execution across multiple delivery formats. Gappelberg noted that the integration of KraftyLabs' engagement capabilities with Nextech3D.ai's existing AI, data, and event infrastructure is expected to unlock new growth opportunities across enterprise, education, and global corporate communications markets. #nextech3d.al #otcqx #nexcf #cse #ntar #EvanGappelberg #ARway #AugmentedReality #SpatialMapping #IndoorNavigation #MapDynamics #EventTech #TradeShowSolutions #TechStocks #ARRevenueGrowth #3DTechnology #ProactiveInvestors #aws #amazonwebservice #tickets #kraftylab